EUVIMEDEUVIMED entdecken
Crossref

IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA

HanJie Yi, YongQing Han, Xia Wang, Qing Li, Le Xiong, ShanFeng Li

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03383-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von HanJie Yi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Drug Resistance, Neoplasm, Paclitaxel, Urinary Bladder Neoplasms. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder urothelial carcinoma (BUC) is associated with poor prognosis and chemoresistance. The RNA-binding protein IGF2BP3 has been implicated in the progression and drug resistance of various cancers, but its role in UC remains underexplored. This study aimed to investigate the role of IGF2BP3 in regulating CENPA mRNA stability and its contribution to UC malignancy and paclitaxel (PTX) resistance. We analyzed human BUC cell lines (UMUC3, T24) and their paclitaxel-resistant counterpart (T24/R). The interaction between IGF2BP3 and CENPA mRNA was assessed using RNA immunoprecipitation (RIP), MeRIP-qPCR, and dual-luciferase reporter assays. RNA stability was measured with actinomycin D treatment. Cell migration, invasion, and clonogenic assays were performed to evaluate the impact of IGF2BP3 and CENPA modulation on tumor behavior. In vivo tumorigenicity and paclitaxel response were evaluated using xenograft mouse models. IGF2BP3 directly binds to m^6A-modified CENPA mRNA and enhances its stability, thereby sustaining its expression in BUC. IGF2BP3 knockdown markedly decreased CENPA mRNA and protein levels and increased paclitaxel sensitivity. CENPA overexpression restored the migratory, invasive, and clonogenic capacities of IGF2BP3-silenced cells under paclitaxel treatment, whereas mutation of the m^6A site abolished this rescue effect, indicating m^6A dependency. In vivo, IGF2BP3 silencing suppressed tumor growth and enhanced paclitaxel sensitivity in T24/R-derived xenografts, which was partially reversed by CENPA overexpression. IGF2BP3 promotes malignant phenotype and paclitaxel resistance in BUC by stabilizing CENPA mRNA. Targeting the IGF2BP3-CENPA axis may provide a novel therapeutic strategy to overcome chemoresistance in BUC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsDrug Resistance, NeoplasmPaclitaxelUrinary Bladder NeoplasmsCarcinoma, Transitional CellHumansAnimalsMiceRNA, MessengerCell Line, TumorXenograft Model Antitumor AssaysAdenosineAntineoplastic Agents, PhytogenicMice, NudeRNA StabilityFemaleCell Movement

Stichwörter der Autor:innen

Bladder urothelial carcinomaCENPADrug resistanceIGF2BP3m6A modificationmRNA stability

Substanzen

RNA-Binding ProteinsIGF2BP3 protein, humanPaclitaxelRNA, MessengerAdenosineAntineoplastic Agents, PhytogenicN-methyladenosine

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China.
  • Department of Oncology, Shangrao People's Hospital, Shangrao City, 334000, Jiangxi Province, China.
  • Department of Nosocomial Infection Management, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang City, 330000, Jiangxi Province, China. lli0117shanfeng@outlook.com.

Zitieren

APA

Yi, H., Han, Y., Wang, X., Li, Q., Xiong, L., & Li, S. (2026). IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. Medical Oncology. https://doi.org/10.1007/s12032-026-03383-7

Vancouver

Yi H, Han Y, Wang X, Li Q, Xiong L, Li S. IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. Medical Oncology. 2026. doi:10.1007/s12032-026-03383-7

BibTeX
@article{Yi2026,
  author = {Yi, HanJie and Han, YongQing and Wang, Xia and Li, Qing and Xiong, Le and Li, ShanFeng},
  title = {IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03383-7}
}
Kostenlos starten →